Alnylam Pharmaceuticals
ALNY
#508
Rank
A$70.43 B
Marketcap
A$533.11
Share price
-0.17%
Change (1 day)
24.64%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): A$0.15

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$0.13. In 2023 the company made an earnings per share (EPS) of A-$5.24 an increase over its 2022 EPS that were of A-$13.80.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.15
2023A-$5.24-62%
2022A-$13.8029.03%
2021A-$10.69-3.36%
2020A-$11.06-8.48%
2019A-$12.097.67%
2018A-$11.2339.74%
2017A-$8.0312.94%
2016A-$7.1138.84%
2015A-$5.12-32.88%
2014A-$7.63259.44%
2013A-$2.12-31.25%
2012A-$3.09

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
A-$1.86-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
A$64.51 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$4.07-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.36-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.08-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$10.93 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$5.50 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
A$0.94 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel